Scientific Industries (SCND) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
29 Dec, 2025Executive summary
The 2024 Annual Meeting will be held virtually on January 22, 2026, to elect directors, amend the equity incentive plan, and ratify the external auditor.
Shareholders of record as of December 16, 2025, are entitled to vote; 11,928,599 shares of common stock are outstanding.
Proxy materials, including the annual report, are available online and by mail.
Voting matters and shareholder proposals
Election of two Class A Directors to serve until the 2027 annual meeting.
Approval sought to amend the 2022 Equity Incentive Plan, increasing available shares to 3,750,000.
Ratification of Berkowitz Pollack Brant Advisors + CPAs as independent auditor for fiscal 2025.
Shareholder proposals for the next annual meeting must be submitted by August 18, 2026.
Board of directors and corporate governance
Board consists of three classes, each serving staggered three-year terms; two Class A directors up for re-election.
Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined charters and independent members.
Shareholders can communicate with the board or specific directors via the corporate secretary.
Board and committee charters are available on the company website.
Latest events from Scientific Industries
- Net loss narrowed and margins improved, but liquidity and funding remain critical concerns.SCND
Q2 20241 Feb 2026 - Net loss narrowed and sales rose, but liquidity and going concern risks remain.SCND
Q3 202413 Jan 2026 - Bioprocessing sales rose 24% in 2024, with cost cuts and a strong pipeline for 2025.SCND
Q4 202425 Dec 2025 - Registering 3.1M shares for resale, company faces losses, liquidity risks, and bioprocessing focus.SCND
Registration Filing29 Nov 2025 - Bioprocessing-focused growth strategy drives losses; 8M-share resale offering targets capital needs.SCND
Registration Filing29 Nov 2025 - 3.1M shares registered for resale as company pivots to bioprocessing amid ongoing losses.SCND
Registration Filing29 Nov 2025 - 3.1M shares registered for resale as company pivots to bioprocessing amid ongoing losses.SCND
Registration Filing29 Nov 2025 - 3.1M shares registered for resale; company pivots to bioprocessing amid ongoing losses.SCND
Registration Filing28 Nov 2025 - Q2 2025 revenue fell 12%, net loss widened, Genie Division sold, and new equity raised.SCND
Q2 202523 Nov 2025